Cleerly joins American Heart Association Center for Health Technology & Innovation Innovators’ Network
American Heart Association consortium advances development of evidence-based health tech solutions
Denver – October 2, 2023 -- Cleerly, the company creating a new standard of care for heart disease, today announced that it has joined the American Heart Association Center for Health Technology & Innovation’s (the Center) Innovators’ Network. The Center is focused on building and fostering health technology relationships to develop innovative and scalable solutions.
The Innovators’ Network is a health care technology consortium that connects entrepreneurs, providers, researchers and payers. Innovators’ Network members also have access to the Association’s digital guidelines, recommendations and best-in-class science as they develop digital healthcare technologies. Members collaborate with the Center in different ways, including the building of models for clinical outcome studies, lowering the significant cost of developing those studies independently, helping connect the science to technology, and providing evidence that a digital platform improves healthcare outcomes – a key concern for providers and payers.
“The Center aims to advance the rapid, efficient, and effective development of healthcare technology,” said Robert A. Harrington, M.D., FAHA, volunteer past president of the American Heart Association (2019-2020), chair of the American Heart Association’s Health Tech Advisory Group for the Center and the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine and provost for medical affairs of Cornell University. “Joining the Innovators’ Network gives members the opportunity to leverage the consortium and work toward broadening and deepening their engagement in this arena.”
Cleerly’s artificial intelligence (AI)-enabled digital platform evaluates coronary computed tomography angiography (CCTA) imaging of the heart, allowing physicians to identify, characterize and quantify atherosclerosis (plaque) buildup in the walls of heart arteries more easily. Cleerly provides a detailed vessel-by-vessel evaluation of stenoses and atherosclerosis and is a shift away from how heart disease has traditionally been assessed by indirect surrogate markers of disease. The personalized reporting provided through Cleerly’s platform can help providers deliver precision treatment across the continuum of heart disease severity, drastically reducing patient costs, but more importantly, improving clinical outcomes.
“It’s an honor for Cleerly to join the Innovators’ Network among so many esteemed organizations in the heart health technology space,” said James K. Min, MD, FACC, FESC, MSCCT, founder and CEO of Cleerly. “We look forward to collaborating with the Network as we continue our clinical outcome studies and work toward a heart attack-free world.”
Cleerly is the company creating a new standard of care for heart disease. Through its FDA-cleared, value-based diagnostic solutions driven by machine intelligence, Cleerly enables comprehensive phenotyping of coronary artery disease, as determined from advanced non-invasive CT imaging. Led by a world-class clinical and technical team, Cleerly enhances health literacy for each and every stakeholder in the coronary care pathway. For more information, please visit: https://www.cleerlyhealth.com.
Cleerly: March 26, 2024
CREDENCE and PACIFIC-1 study data demonstrate potential power of AI-QCT ISCHEMIA
Cleerly: March 5, 2024
Company’s AI-enabled technology for future heart attack risk assessment accepted into FDA’s TAP Pilot and to be validated in landmark TRANSFORM trial
Cleerly: February 22, 2024
FDA-cleared Cleerly ISCHEMIA will assist healthcare professionals in clinical diagnosis and decision making for coronary artery disease
Cleerly
